A Phase 3 interventional study of Dapagliflozin 10 MG Oral Tablet [Farxiga] and One tablet of placebo of dapagliflozin 10 mg in Heart Failure and Chronic Kidney Disease Post-ICU, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.
Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 10th largest by planned enrollment, is one of 5 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 17 of the 18 other live ones, and was the 54th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 12+
Yale University · Sites in United States
Ages 18–85 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 20 · Phase 4 22
First in 2015; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 100 across the 59 interventional studies. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 59 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
31 studies in Heart Failure by Assistance Publique - Hôpitaux de Paris: 10 open now, 12 under way, 2 of them phase 3. Of 15 finished, 0 (0%) have results posted.
Among the 31 studies in Heart Failure by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 8 of the 11 other live ones, and was the 29th registered.
Assistance Publique - Hôpitaux de Paris’s Heart Failure studies by the year they started, since 2000.
4 of the studies testing dapagliflozin in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06304857Phase 34th Military Clinical Hospital with Polyclinic, PolandCardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL | 2026-12-31 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing dapagliflozin in Heart Failure, from their registry updates:
Among Assistance Publique - Hôpitaux de Paris’s 31 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
Several millions of patients are admitted to ICUs in Europe or USA each year. We and others, have shown that patients discharged from intensive care units (ICU) have a high incidence of cardiovascular and/or renal events and high mortality rate (22%) during the year following ICU discharge. Furthermore, a very recent meta-analysis found an excess hazard of late cardiovascular events which persists for at least 5 years following hospital discharge in sepsis survivors. Hence, many international ICU societies recommended investigating and improving post-ICU outcome with scarce guidance. We demonstrated that the proportion of ICU patients dying or presenting cardiovascular events within the year following ICU discharge is reported \~25% [2], reaching \~40% in some studies when considering patients with acute kidney injury (AKI). Plasma biomarkers at ICU discharge have good predictive value and patients with increased kidney or cardiovascular biomarkers display high risk of such events. In addition, we and others demonstrated that AKI or sub-AKI (patient not meeting the AKI definition but with an increased kidney related biomarker) could induce remote cardio-vascular injury and fibrosis, which may be involved in the poor long-term prognosis of ICU-acquired AKI. We hypothesize that strategy that prevent worsening in cardiovascular and/or renal injuries and/or in cardiovascular consequences of sub-AKI and AKI after ICU discharge improve long-term outcomes in ICU survivors. SGLT2 inhibitors are widely recognized as key drugs to protect the kidney and/or the myocardium in chronic diseases such as diabetes or heart failure. Cardio protective effect of SGLT2 inhibitors is optimal in patients with higher cardiac biomarker.
Phase III study Prospective, multicenter, superiority, double-blind, randomized controlled study with two arms (1:1).
Every patient will be screened in the 48h before ICU discharge for trial inclusion and non-inclusion criteria until 72h hours after ICU discharge. After providing written informed consent, patients will be randomly assigned to receive either dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in accordance with the sequestered, fixed-randomization schedule, with the use of balanced blocks to ensure an approximate 1:1 ratio of the two regimens for one year.
Four visits are planned, one at inclusion (V0), one at 6 months (V1), one at the end of the treatment (V2 at one year), one 6 weeks after the end of the treatment (V3, end of the study) and two phone calls at 3 (Phone call 1) and 9 months (phone call 2).
At 6 months (V1) and at 12 months (V2) visits, a clinical exam and biological analysis will be performed at hospital (i.e., HbA1c, glucose level, ionogram, NT-proBNP or BNP, serum creatinine, hematocrit and pregnancy urinary test) by anesthesiologists, cardiologists or nephrologists, to assess primary and secondary endpoints, including eGFR.
At 12 months + 6 weeks (V3) visit, a clinical exam and biological analysis will be performed at hospital (i.e., glucose level, NT-proBNP or BNP, serum creatinine) by anesthesiologists, cardiologists or nephrologists, to assess primary and secondary endpoints, including eGFR.
The phone calls, at 3 and 9 months, will be made by the designated persons and respecting the confidentiality and security of the data collected.
At inclusion (V0) and at 6 months (V1) the treatment will be deliver for the next 6 months. At 6 months (V1), the patient will pick up his treatment at the hospital.
Primary endpoints will be assessed at 6 and 12 months visit and phone calls (3 and 9 months).
Secondary endpoints will be assessed at each visit and phone calls (3, 6, 9, 12 and 12 + 6 weeks).
eGFR (glomerular filtration rate) will be assessed only at 6, 12 months and 12 + 6 weeks. The eGFR (glomerular filtration rate) will not be assessed at phone calls.
At each visit and phone calls, adverse events and severe adverse events will also be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The inclusion of WOCBP requires use of a highly effective contraceptive measure :
combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
progestogen-only hormonal contraception associated with inhibition of ovulation
The above mentioned risk mitigation measures (contraception) should be maintained during treatment and until the end of relevant systemic exposure.
** a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
Patient for whom treatment with Dapagliflozine is strongly recommended according to recent international guidelines:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..
Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]
One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.
Drug: One tablet of placebo of dapagliflozin 10 mg
One tablet of dapagliflozin 10 mg will be administered once daily from randomization and for 12 months period +/- 15 days..
One tablet of placebo of dapagliflozin 10 mg will be administered, per os, once daily from randomization and for 12 months period ± 15 days.
All-cause mortality
Time frame: Within the year after randomization
Unscheduled hospital hospitalization for heart failure
All potential hospitalizations for heart failure should be recorded in the eCRF and submitted to adjudication. The Clinical Event Adjudication (CEA) committee members will adjudicate the events as specified in the (CEA) Charter.
Time frame: Within the year after randomization
Decrease of eGFR by more than 50% from ICU discharge and/or end stage kidney disease defined as an eGFR<15ml/min/1.73m² and/or initiation of renal replacement therapy and/or kidney transplantation
Dialysis, eGFR events (\<15 mL/min/1.73m²; ≥50% decline in eGFR) will be recorded in the eCRF and submitted for adjudication. eGFR baseline is defined as the local laboratory value at inclusion visit. The eGFR will be calculated using CKD-EPI equation without race coefficient \[87, 88\].
Time frame: Within the year after randomization
Unscheduled hospital hospitalization for acute heart failure
Time frame: Within the year after randomization
Unscheduled hospital hospitalization for stroke
Time frame: Within the year after randomization
Unscheduled hospital hospitalization for acute coronary syndrome
Time frame: Within the year after randomization
Occurrence of severe chronic kidney disease
Defined as eGFR \<30 ml/min/1.73m2
Time frame: Within the year after randomization
• Decrease of estimated glomerular filtration rate of more than 50% from baseline
Time frame: Within the year after randomization
New episode of acute kidney injury (according to the KDIGO criteria) requiring hospitalization
Time frame: Within the year after randomization
Occurrence of end stage kidney disease defined (eGFR<15ml/min/1.73m2) and/or initiation of renal replacement therapy and/or kidney transplantation
Time frame: Within the year after randomization
Change in NT-proBNP (pg/mL) from baseline to end of study
Time frame: Between 12 months (end of treatment) and 12 months + 6 weeks (end of study)
Occurrence of cardiovascular events
The participants sites should record potential strokes and transit ischemic attacks (TIAs) in the eCRF and submit for adjudication. The CEA committee members will adjudicate all potential cerebrovascular events to decide if they qualify as stroke according to the criteria defined in the CEA charter
Time frame: Within the year after randomization
Occurrence of renal events
Time frame: Within the year of treatment
Urinary tract infection
All potential events of urinary tract infection will be recorded in the eCRF and submitted to the CEA.
Time frame: Within the year after randomization
Necrotizing fasciitis
All potential events of necrotizing fasciitis will be recorded in the eCRF and submitted to the CEA.
Time frame: Within the year after randomization
Symptomatic ketoacidosis
This outcome is defined as Arterial pH \<7.3 and Ketone-positive urine and Anion gap \>10 mEq/L and Drowsy, stupor or coma All potential events of ketoacidosis will be recorded in the eCRF and submitted to the CEA.
Time frame: Within the year after randomization
Major hypoglycaemia
This outcome is defined as gycemia\<3 mmol/l) and any episode of hypoglycemia for which assistance was needed, all potential major hypoglycaemia will be recorded in the eCRF and submitted to the CEA.
Time frame: Within the year after randomization
Death of any cause
Time frame: Within the year after randomization
Occurrence of global outcome events
Events will be recorded in the eCRF and submitted to adjudication by the CEA committee for each event type. The adjudication process will ensure the thorough evaluation and classification of events based on the clinical and laboratory criteria specified in the study protocol.
Time frame: Within the year of treatment
Plan to share: Yes — Individual participant data (IPD) will be shared. The data will be anonymized to protect participants' privacy. Researchers may request access to the data by contacting the Steering Committee, which will review the request within two months. The data will be available one year after publication.
Time frame: The data will be available one year after publication, for 5 years
Started Dec 2025 (actual). Primary completion is estimated for Jan 2029, 37 months after the start.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 37 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin
Assistance Publique - Hôpitaux de Paris →